Copy Link Print Information

Cisplatin

(Synonyms: cis-Platinum; CDDP; cis-Diaminodichloroplatinum)
837 Cited Publications
Customer Review

Based on 837 publication(s) in Google Scholar

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy.

For research use only. We do not sell to patients.

  • Purity: 99.30%
  • CAS No.: 15663-27-1
  • Formula: Pt(NH3)2Cl2
  • Molecular Weight:300.05
  • Storage:

    4°C, protect from light

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

  • Cisplatin Chemical Structure
    Cisplatin Chemical Structure
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
  • Experimental Validation Results for Cisplatin
CAS No.: 15663-27-1
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Cisplatin

More
Customer Validation & Images
IHCWBIn Vivo Efficacy StudyIFRT-PCRCell Proliferation/Viability Assay
  • IHC
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • RT-PCR
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All Lipoxygenase Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Cisplatin Chemical Structure
    Cisplatin Chemical Structure
    1/16
  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jun 20;11(25):eadt3075. [Abstract]

    Customer Validation
     Brain slices of mice were stained with hematoxylin andeosin (H&E) at the endpoint. BCBM model mice, either cisplatin (4 mg/kg, intraperitoneally) or ʟ-ASNase (L-Asparaginase; 0.2 mg per mouse, intraperitoneally) was administered weekly or every 2 days for 2 weeks, respectively.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jun 20;11(25):eadt3075. [Abstract]

    Customer Validation
     BLI was conducted at regular intervals. Representative BLI images and line chart of radiance. BCBM model, Mice were administered cisplatin (4 mg/kg, intraperitoneally) weekly or ʟ-ASNase (0.2 mg per mouse, intraperitoneally) every 2 days.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Oct 31;23(1):243. [Abstract]

    Customer Validation
     Cisplatin (2 μg/mL; 24-72 h) combined with Venetoclax (10-160 μM; 12-72 h) and Hydroxychloroquine (12.5-50 μM; 12-72 h) significantly inhibits the growth of H446/cDDP cells.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Mar:73:101059. [Abstract]

    Customer Validation
     Proliferation capacity of cells assessed using colony formation experiments after treatment with 10 μM cisplatin in combination with 10 μM 2-DG or 5 μM oxamate or 15 μM Nala.
    2-DG and oxamate synergize with cisplatin could inhibit BCa cell proliferation and colony-forming ability.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Nov 12;18(45):31401-31420. [Abstract]

    Customer Validation
     Cisplatin (5-30 μM; 24 h) exhibits an IC50 value of 14.56 μM for inhibiting the viability of A549 cells.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Nov 12;18(45):31401-31420. [Abstract]

    Customer Validation
     Cisplatin (5-30 μM; 24 h) demonstrates an IC50 value of 7.41 μM for inhibiting the viability of H1299 cells.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]

    Customer Validation
     The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

    Customer Validation
     Normal FHs 74 cell lines were pretreated with Mannose (20 mM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

    Customer Validation
     Normal FHs 74 cell lines were pretreated with Mannose (20 mM) and DON (40 μM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

    Customer Validation
     Normal NRK-52E cell lines were pretreated with Mannose (20 mM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922. [Abstract]

    Customer Validation
     Normal NRK-52E cell lines were pretreated with Mannose (20 mM) and DON (40 μM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836. [Abstract]

    Customer Validation
     Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) increases the protein expression of p53 and p21 in ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836. [Abstract]

    Customer Validation
     Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) suppresses the proliferation of ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2023 Aug 20:669:61-67. [Abstract]

    Customer Validation
     Cisplatin (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2021 Apr 4;20(1):62. [Abstract]

    Customer Validation
     LL2 cells were treated by cisplatin (2.5 μM and 5 μM) for 24 h and collected. The relative mRNA expression of CXCL1, CXCL2, CXCL3 and MIF of LL2 cells following cisplatin treatment.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

    Customer Validation
     IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

    Customer Validation
     Genotoxic stress-induced β-catenin signaling is activated via a TCF- or FOXO-independent mechanism. Representative images of the subcellular localization of β-catenin in the indicated cells treated with CPT (10 μM, 1 h), IR (10 Gy), and CDDP (10 μM, 1 h), as analyzed by immunofluorescence staining.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705. [Abstract]

    Customer Validation
     WT and S47 E1A/RAS cells are treated with 10μM CDDP for 24 hours in the presence or absence of the protein synthesis inhibitor Cycloheximide (2.5 g/mL). Cell lysates are subjected to Western blot analysis, and immunoblotted for cleaved caspase-3, p53, p21, and HSP90 (loading control). CDDP: cisplatin

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705. [Abstract]

    Customer Validation
     WT and S47 E1A/RAS cells are treated with 10 M Cisplatin (CDDP) for 24 hours. Cells are then fractionated into three fractions: whole cell lysate (W), mitochondria (M), and cytosol (C).

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2018 Aug 24:682:112-117. [Abstract]

    Customer Validation
     After treatment of CDDP with or without the autophagy inhibitor CQ, the expression of LC3-II in the CQ+CDDP group is less than that in the CQ group but is higher than that in the CDDP group at 24 h and 96 h.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Feb;15(2):2583-2589. [Abstract]

    Customer Validation
     MLN4924 increases CDDP induced apoptosis of esophageal cancer cells. EC1 and Kyse450 cells are treated with 1.6 μg/mL CDDP alone or in combina¬tion with 0.3 μM MLN for 72 h. Cleaved PARP are detected by western blotting.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 May;15(5):6469-6474. [Abstract]

    Customer Validation
     MDA-MB-231 cells are grown and treated with CC-5013 (Len), Cisplatin (Cis), or their combination for 72 h and then subjected to western blot analysis.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Aug:36:108-116. [Abstract]

    Customer Validation
     PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), Cisplatin (for 24 h) and NSC 123127 (for 10 h) as indicated, followed by immunoblotting with the antibodies.

  • 1/16

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Apr 25;8(17):29125-29137. [Abstract]

    Customer Validation
     Knockdown of ROC1 significantly enhances CDDP-induced apoptosis. TE1 and Kyse450 cells are transfected with siROC1 for 48 h and then treated with 1 μg/mL CDDP for 48 h. Knockdown efficiency and cleaved PARP are assessed by western blotting analysis. Protein expression is quantified and statically analyzed.

  • Cisplatin